N-Acetylcysteine for COVID-19: A Potential Adjuvant Therapy

Authors

  • Mia Elhidsi Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia
  • Fanny Fachrucha Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia https://orcid.org/0000-0001-9450-2180
  • Rizky Yudha Irawan Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia https://orcid.org/0000-0003-4187-919X

DOI:

https://doi.org/10.17532/jhsci.2020.1156

Keywords:

antioxidant, COVID-19, glutathione, N-acetylcysteine, oxidative stress

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) infection or known as coronavirus disease 2019 (COVID-19) is a highly infectious disease that has been declared as a world pandemic by WHO. Although the majority of patients only experience mild symptoms, older patients and those with comorbidities are in the risk of falling into critically ill and even death. This is thought to correlate with systemic inflammatory response and oxidative stress imbalance. N-acetylcysteine (NAC) is recognized as a potent mucolytic, yet its lesser-known function as an antioxidant is a precursor of glutathione. Basic aspects and either in vivo or in vitro studies showed various mechanisms of NAC acting as a counterbalance in viral infections and its role in decreasing inflammation and oxidative stress. High-dose NAC is reported to be effective as an antioxidant in pneumonia, influenza, sepsis, and acute respiratory distress syndrome. Early evidence in COVID-19 patients showed that NAC could be beneficial. This review gives the scientific background in considering NAC as an adjuvant treatment for COVID-19.


Downloads

Download data is not yet available.

Author Biographies

  • Mia Elhidsi, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia

    Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Indonesia

    Persahabatan National Respiratory Referral Hospital, Jakarta

    Staff of COVID-19 Task Force, Indonesian Society of Respirology

    Consultant of Respiratory Critical Care

  • Fanny Fachrucha, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia

    Division of Immunology

    Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Indonesia - Persahabatan National Respiratory Referral Hospital, Jakarta

    Staff of COVID-19 Task Force, Indonesian Society of Respirology

    Consultant of Pulmonary Immunology

  • Rizky Yudha Irawan, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia

    Faculty of Medicine, Universitas Indonesia - Persahabatan National Respiratory Referral Hospital, Jakarta.

    Fellowship at Pulmonary and Respiratory Medicine, Universitas Indonesia

Downloads

Published

07.01.2021

Issue

Section

Reviews

Categories

How to Cite

1.
N-Acetylcysteine for COVID-19: A Potential Adjuvant Therapy. JHSCI [Internet]. 2021 Jan. 7 [cited 2024 Jun. 18];11(1):1-6. Available from: https://www.jhsci.ba/ojs/index.php/jhsci/article/view/1156